TB-500 clinical & cardiac research — what reached trials

Most of the compounds in the research-peptide category never came close to a human clinical trial — the evidence is rodent, in-vitro, or anecdotal. Thymosin β4, the parent protein behind TB-500, is one of the rare exceptions. It carried a multi-year biotech clinical program into phase-2 study in a narrow group of indications, and it sits behind a separate preclinical cardioprotection literature. That distinction is the single most interesting thing about TB-500 — and it is also where honesty matters most, because reaching the clinic is not the same as being approved.

Why TB-500 is unusual: it reached the clinic

The research-peptide market is full of compounds whose entire evidence base is preclinical. Tβ4 is different in one specific way: by the early 2000s it had already moved from the laboratory bench toward an actual clinical-trial program. A 2004 review noted, in plain terms, that Tβ4 “is currently in clinical trials for wound repair” — capturing the moment the molecule crossed from a decade of preclinical tissue-recovery research into a structured clinical-development effort [3].

That is a meaningfully higher bar than most peptides in this catalogue clear. A clinical-development program means a sponsor committed to manufacturing the compound to clinical-grade specification, registering trials, and recruiting human participants under a defined protocol. Whether the program ultimately succeeded is a separate question — and the honest answer, covered below, is that it did not reach registration. But the fact that it got that far is what makes TB-500 worth a separate clinical-history article rather than a single sentence in the parent synopsis.

The RegeneRx / ophthalmic clinical program

The clinical-development sponsor was RegeneRx Biopharmaceuticals, which ran a multi-year program for Tβ4 across three broad areas — dermal-ulcer (skin) indications, corneal-wound indications, and dry-eye. Of these, the ophthalmic strand progressed furthest toward the clinic. Sosne (2018, Expert Opinion on Biological Therapy) reviews the translation of Tβ4 in the eye specifically, framing it as a journey “from bench to bedside” — from the early corneal tissue-recovery models through to early clinical study of the topical eye formulation [1].

There is a reason the eye was the indication that got closest. The cornea is a small, accessible, externally-dosed tissue with well-validated injury-and-recovery endpoints, and a topical eye-drop formulation sidesteps the systemic-exposure questions that complicate an injectable. That made the ophthalmic indication the most tractable place to test the extracellular tissue-recovery biology of Tβ4 in humans — which is why it, rather than the systemic dermal or cardiac work, is the strand that reached early clinical study.

The ophthalmic program is the high-water mark for Tβ4 in humans — a real topical formulation in early clinical study, not a preclinical extrapolation. It is also where the honest limits of the story become clearest.

Cardioprotection research

The second distinctive strand is cardiac. Tβ4 has been investigated for cardioprotection — preserving and supporting heart tissue in the setting of injury — and this is the body of work that most often gets cited as the molecule’s most ambitious research direction. Pipes and colleagues (2016, Vitamins and Hormones) review cardioprotection by Tβ4 in cardiac-injury models, describing the dual profile that makes it unusual among single-peptide candidates: signals for both cardiomyocyte survival and vascular regeneration after injury [2].

The key qualifier here is that the cardiac work is preclinical. Unlike the ophthalmic strand — which reached early clinical study — the cardioprotection literature sits in cell systems and animal cardiac-injury models. It is mechanistically interesting and reasonably consistent in those models, but it has not been carried into a registered late-stage human cardiac-indication trial. The dual myocardial-survival-plus-angiogenic profile is what keeps academic groups interested; the absence of a phase-3 cardiac program is what keeps the claim preclinical.

Signals, not approval — what this does and does not mean

It is easy to over-read “reached the clinic.” Here is the honest accounting of what the clinical and cardiac record actually supports — and what it does not:

• What it means. Tβ4 cleared a bar most research peptides never approach — a sponsor-run clinical-development program, with the ophthalmic indication reaching early clinical study and the dermal-ulcer and dry-eye indications reaching phase-2 readouts that showed efficacy signals.
• What it does not mean. The phase-2 signals did not advance to phase-3 registration trials, and no regulatory approval followed. The reasons in the public record are not fully resolved — whether business decisions, trial-design factors, or effect-size considerations drove the stop is not clearly documented.
• The cardiac caveat. The cardioprotection work is preclinical. It has not been tested in a registered late-stage human cardiac trial; the cardiac-injury evidence is from models, not patients.
• The bottom line. Tβ4 / TB-500 is not an approved medicine in any major jurisdiction. It remains a research compound — supplied for research use only, not for human consumption.

Related reading in the TB-500 cluster

For the actin-sequestering biology and the extracellular angiogenesis pathways behind these effects, see TB-500 mechanism research. For the doses and routes used in the preclinical and trial work, see TB-500 dosing research protocols. For how TB-500 compares to the other major tissue-recovery research peptide, see BPC-157 vs TB-500. Overview: TB-500 synopsis, the TB-500 5 mg research vial, and the research peptides in the UAE hub.

Further reading

Peer-reviewed citations used inline:

• [1] Sosne — Expert Opin Biol Ther 2018. Thymosin beta 4 and the eye: the journey from bench to bedside. DOI 10.1080/14712598.2018.1486818.
• [2] Pipes, et al. — Vitam Horm 2016. Cardioprotection by Thymosin Beta 4. DOI 10.1016/bs.vh.2016.04.004.
• [3] Philp, Goldstein, Kleinman — Mech Ageing Dev 2004. Thymosin beta4 promotes angiogenesis, wound healing, and hair-follicle development; notes Tβ4 in clinical trials for wound repair. DOI 10.1016/j.mad.2003.11.005.

Last reviewed 11 June 2026. Wellness Labs supplies TB-500 as research-grade lyophilised powder for non-clinical investigation — for research use only, not for human consumption. Editorial inbox: info@uaewellnesslab.com.